定义IgA肾病中的疾病修饰:迈向管理范式的转变
本文综述探讨如何在IgA肾病中定义「疾病修饰」,基于保护肾单位并避免患者一生中进展至肾衰竭的前提,并分析如何有意义地评估疾病修饰,包括对死亡率、肾衰竭、eGFR、尿蛋白或白蛋白、镜下血尿及IgA肾病病理标志物的影响。进一步讨论多方位管理策略,同时针对导致肾单位丢失的IgA肾病特异性过程及对肾单位丢失的通用适应不良反应。
要点
- 疾病修饰应以保护肾单位、避免终生进展至肾衰竭为核心前提。
- 评估疾病修饰需综合死亡率、肾衰竭、eGFR、尿蛋白/白蛋白、镜下血尿及病理标志物。
- IgA肾病管理应采用多方位策略,兼顾特异性过程与通用适应不良反应。
核心结论
- IgA肾病中「疾病修饰」缺乏统一定义,本综述基于保护肾单位并避免患者终生进展至肾衰竭的前提提出定义思路。
研究设计与样本
- 本文为综述,讨论IgA肾病中疾病修饰的定义及评估方法,未涉及具体研究样本。
主要发现
- 疾病修饰可通过干预对死亡率、肾衰竭、eGFR、尿蛋白或白蛋白、镜下血尿及IgA肾病病理标志物的影响来评估。
- IgA肾病管理应采用多方位方法,同时针对IgA肾病特异性过程及肾单位丢失后的通用适应不良反应。
临床怎么用
- 临床中评估IgA肾病干预是否具有疾病修饰作用时,应综合肾衰竭、eGFR、蛋白尿、血尿及病理标志物等多维度指标。
- 管理策略应兼顾IgA肾病特异性治疗与针对肾单位丢失后适应不良反应的通用措施。
局限性
- 原文指出IgA肾病中「疾病修饰」缺乏共识定义,且合适标志物尚不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IgA nephropathy (IgAN) is a rare, chronic, immune-mediated kidney disease characterized by a slow, progressive decline in kidney function. As a disease without an existing cure and a leading cause of chronic kidney disease (CKD) and kidney failure, IgAN requires effective interventions for disease modification. However, identifying interventions as "disease modifying" is challenging in IgAN because of a lack of consensus on the term and uncertainty about suitable markers by which "disease modification" should be defined. This review discusses how "disease modification" could be defined in IgAN, based on the simple premise of the need to preserve nephrons and avoid progression to kidney failure within the patient's lifetime. In addition, how disease modification can be meaningfully assessed (e.g., the impact of an intervention on mortality and kidney failure, estimated glomerular filtration rate [eGFR], urinary protein or albumin, nonvisible [microscopic] hematuria, and markers of underlying IgAN pathology) is examined. Further, the concept of a multifaceted approach to IgAN management is discussed, targeting both the IgAN-specific processes leading to nephron loss and the generic maladaptive responses to IgAN-induced nephron loss.
引用
- Barratt J, Mariani LH, Radhakrishnan J, et al. Defining Disease Modification in IgA Nephropathy: Toward a Paradigm Shift in Management. Kidney Int Rep. 2025. PMID: 41426049. doi:10.1016/j.ekir.2025.09.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。